Ask AI
ProCE Banner Activity

Medical Minute 3: Evolving Treatment Landscape for Early-Stage TNBC With and Without gBRCAm

Slideset

These slides review the evolving treatment landscape for early-stage TNBC with and without gBRCA mutation, including guideline-recommended options, emerging treatments, and strategies for optimizing health equity and guideline-concordant care.

Released: June 19, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Tigerlily Foundation

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Tigerlily Foundation

ProCE Banner

Target Audience

This activity is intended for oncologists, nurses, nurse practitioners, physician associates, pharmacists, and other healthcare professionals who care for patients with early breast cancer. This educational program is also intended to reach patients with early breast cancer and their caregivers.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recommend the optimal neo/adjuvant treatment strategy for each patient with EBC, considering patient/disease factors, evidence, approvals, and guidelines

  • Collaborate with patients, caregivers, and the multidisciplinary team to effectively monitor and manage treatment-related toxicities experienced by patients with EBC

  • Apply shared decision-making and communication strategies to support patient adherence and persistence on neo/adjuvant treatment for EBC

  • Appraise the clinical implications of emerging evidence for neo/adjuvant treatments leveraging antibody–drug conjugates, immunotherapies, and other novel agents under investigation in EBC